Show simple item record

FieldValueLanguage
dc.contributor.authorShu, Zixinen_AU
dc.contributor.authorZhou, Yanaen_AU
dc.contributor.authorChang, Kaien_AU
dc.contributor.authorLiu, Jifenen_AU
dc.contributor.authorMin, Xiaojunen_AU
dc.contributor.authorZhang, Qingen_AU
dc.contributor.authorSun, Jingen_AU
dc.contributor.authorXiong, Yajuanen_AU
dc.contributor.authorZou, Qunshengen_AU
dc.contributor.authorZheng, Qiguangen_AU
dc.contributor.authorJi, Jinghuien_AU
dc.contributor.authorPoon, Josiahen_AU
dc.contributor.authorLiu, Baoyanen_AU
dc.contributor.authorZhou, Xuezhongen_AU
dc.contributor.authorLi, Xiaodongen_AU
dc.date.accessioned2020-09-24
dc.date.available2020-09-24
dc.date.issued2020en_AU
dc.identifier.urihttps://hdl.handle.net/2123/23435
dc.description.abstractCoronavirus disease 2019 (COVID-19) is now pandemic worldwide and has heavily overloaded hospitals in Wuhan City, China during the time between late January and February. We reported the clinical features and therapeutic characteristics of moderate COVID-19 cases in Wuhan that were treated via the integration of traditional Chinese medicine (TCM) and Western medicine. We collected electronic medical record (EMR) data, which included the full clinical profiles of patients, from a designated TCM hospital in Wuhan. The structured data of symptoms and drugs from admission notes were obtained through an information extraction process. Other key clinical entities were also confirmed and normalized to obtain information on the diagnosis, clinical treatments, laboratory tests, and outcomes of the patients. A total of 293 COVID-19 inpatient cases, including 207 moderate and 86 (29.3%) severe cases, were included in our research. Among these cases, 238 were discharged, 31 were transferred, and 24 (all severe cases) died in the hospital. Our COVID-19 cases involved elderly patients with advanced ages (57 years on average) and high comorbidity rates (61%). Our results reconfirmed several well-recognized risk factors, such as age, gender (male), and comorbidities, as well as provided novel laboratory indications (e.g., cholesterol) and TCM-specific phenotype markers (e.g., dull tongue) that were relevant to COVID-19 infections and prognosis. In addition to antiviral/antibiotics and standard supportive therapies, TCM herbal prescriptions incorporating 290 distinct herbs were used in 273 (93%) cases. The cases that received TCM treatment had lower death rates than those that did not receive TCM treatment (17/273 = 6.2% vs. 7/20= 35%, P = 0.0004 for all cases; 17/77= 22% vs. 7/9= 77.7%, P = 0.002 for severe cases). The TCM herbal prescriptions used for the treatment of COVID-19 infections mainly consisted of Pericarpium Citri Reticulatae, Radix Scutellariae, Rhizoma Pinellia, and their combinations, which reflected the practical TCM principles (e.g., clearing heat and dampening phlegm). Lastly, 59% of the patients received treatment, including antiviral, antibiotics, and Chinese patent medicine, before admission. This situation might have some effects on symptoms, such as fever and dry cough. By using EMR data, we described the clinical features and therapeutic characteristics of 293 COVID-19 cases treated via the integration of TCM herbal prescriptions and Western medicine. Clinical manifestations and treatments before admission and in the hospital were investigated. Our results preliminarily showed the potential effectiveness of TCM herbal prescriptions and their regularities in COVID-19 treatment.en_AU
dc.language.isoenen_AU
dc.subjectCOVID-19en_AU
dc.subjectCoronavirusen_AU
dc.titleClinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient casesen_AU
dc.typeArticleen_AU
dc.identifier.doi10.1007/s11684-020-0803-8
dc.relation.otherMinistry of Science and Technology of the People's Republic of Chinaen_AU


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.